ADS-TEC Energy (NASDAQ:ADSEW) Stock, Quote.Headers.trade-ideas

ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services which enable the customer to control and manage the system. Geographically, it derives a majority of its revenue from Europe.

ADS-TEC Energy PLC

Trading Ideas

LASE

Laser Photonics Shares Resume Trade

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.knightscope.com%2F&amp;esheet=54120488&amp;newsitemid=20240911435090&amp;lan=en-US&amp;anchor=Knightscope%2C+Inc.&amp;index=1&amp;md5=06caadda822f35649f916c192a9629e0">Knightscope, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) ("Knightscope" or the "Company"), an innovator in robotics and artificial intelligence ("AI") technologies focused on public safety, today announces two new deployments of its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.knightscope.com%2Fproducts%2Fk5&amp;esheet=54120488&amp;newsitemid=20240911435090&amp;lan=en-US&amp;anchor=5th+Generation+K5+Autonomous+Security+Robot&amp;index=2&amp;md5=7c27dd9e81499952cbca226e29d8efd6">5th Generation K5 Autonomous Security Robot </a>("ASR") at a Louisiana casino and an international airport in Texas.
The casino is the 10th property to receive Knightscope's ASRs under a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.knightscope.com%2Fnews-releases%2Fnews-release-details%2Fknightscope-provide-penn-entertainment-technology-services&amp;esheet=54120488&amp;newsitemid=20240911435090&amp;lan=en-US&amp;anchor=larger+master+agreement+announced+in+2023&amp;index=3&amp;md5=e11bd7cc793bb290b5d96dbb4e6f46f4">larger master agreement announced in 2023</a> with an entertainment company and operator of integrated entertainment, sports content, and casinos. The master agreement enabled corporatewide expansion of Knightscope technologies to 43 properties across the United States.

News

KSCP

Knightscope Deploys Two New 5th Generation K5 Autonomous Security Robot At A Louisiana Casino And An International Airport In Texas

Benchmark analyst Chris Kuhn reiterates Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Hold.

Reiteration

Analyst Ratings

ODFL

Benchmark Reiterates Hold on Old Dominion Freight Line

Guidance

Modine Manufacturing Targets FY27 Revenue Of $3.2B-$3.5B

Loop Capital analyst Anthony Chukumba reiterates Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Buy and maintains $77 price target.

Price Target

Loop Capital Reiterates Buy on Academy Sports, Maintains $77 Price Target

PLCE

Children's Place Shares Resume Trade

BCTX

BriaCell Therapeutics Shares Resume Trade

Laser Photonics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -23.5%

Children's Place Shares Halted On Circuit Breaker To The Upside, Stock Now Up 53.1%

In a recent development, Amazon founder, Jeff Bezos, has found himself indirectly involved in a $6 million lawsuit following his purchase of a mansion in Miami.
Leo Kryss, co-founder of Brazilian toy company Tectoy, has filed a lawsuit against real estate brokerage Douglas Elliman over a $79 million mansion sale to Bezos, The Wall Street Journal <a href="https://www.wsj.com/real-estate/luxury-homes/jeff-bezos-indian-creek-home-lawsuit-3403cdc7">reported</a> on Tuesday.
Kryss had listed his seven-bedroom mansion on Indian Creek Island, Miami, for $85 million in May 2023. The property, which includes a home theater, wine cellar, library, and pool, is adjacent to a $68 million three-bedroom house that Bezos bought in June 2023.
When Kryss received an offer for the property, he suspected that his new neighbor, Bezos, was the buyer. However, Jay Parker, the Florida CEO of Douglas Elliman, assured Kryss that Bezos was not the buyer and that the offer would not exceed $79 million.
See Also: <a href="https://www.benzinga.com/news/24/09/40764734/mary-trump-donald-trump-could-be-incredibly-dangerous-why-muted-mic-wont-be-advantage-for-ex-preside?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mary Trump: Donald Trump Could Be &#8216;Incredibly Dangerous&#8217;: Why Muted Mic Won&#8217;t Be Advantage For Ex-President At Tuesday Debate</a>
After selling his mansion for $6 million less than its list price, Kryss discovered that the buyer was indeed connected to Bezos. Kryss is now suing Douglas Elliman, which earned over $3 million in commission from the sale, claiming that knowledge of Bezos&#8217; intention to buy adjacent properties would have significantly influenced his decision-making.
Douglas Elliman&#8217;s Parker stated in an email to Kryss that he was also unaware of Bezos&#8217; identity as the buyer. The Journal reported that the property was believed to be purchased by the family of Benny Klepach, the mayor of Indian Creek Village.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Real Estate

Seller Of $79M Mansion To Jeff Bezos Says He Was Deceived, Files Lawsuit Over Lost Millions Against Real Estate Firm That Brokered The Deal

Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Phase 3 LIBERTY-CUPID Study C of Dupixent (dupilumab) <a href="https://www.benzinga.com/pressreleases/24/09/g40807674/dupixent-dupilumab-phase-3-trial-confirms-significant-improvements-in-itch-and-hives-for-patients-">was successful</a>. 
The study met the primary and key secondary endpoints for uncontrolled, biologic-naïve chronic spontaneous urticaria (CSU) receiving background therapy with antihistamines.
CSU is a chronic skin condition that causes hives and persistent itch. The positive trial confirms <a href="https://www.globenewswire.com/Tracker?data=oJfzeZikg10RZeSxzO67FTJgqO763K5kNdrm3HdSiqcD40rtdT3jzNA6fNFwjx6Nc4nhzD2dSQSvLQl3HyV4gYDP3X_suaBGqveOhY9q9Eer6rQOCE73MRR2wMX6cgXvQSFj_5ZktjzZKetwTtPHX37P_7ZxvG1ZhUGAYdI00TOJBZTY_y71Tyf7nSjtOpkcgqOj0D40hUijMplzH4mPEQ==" target="_blank" rel="noreferrer noopener">results</a> from Study A, the first Phase 3 trial of Dupixent in this setting.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40109548/regeneron-pharmaceuticals-q2-earnings-exceed-estimates-driven-by-its-top-selling-eczema-and-eye-d" rel="noreferrer noopener">Regeneron Pharmaceuticals&#8217; Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs</a>.
Earlier this year, Japan was the first country in the world to&nbsp;approve&nbsp;and launch Dupixent for adult and adolescent CSU patients based on the results from Study A.
At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows:
<ul>
<li>8.64-point reduction in itch severity from baseline with Dupixent versus a 6.10-point reduction with placebo.</li>
<li>Dupixent reduced the severity of urticaria activity (itch and hive) by 15.86 points from baseline compared to 11.21 points with placebo.</li>
<li>30% of Dupixent-treated patients reported no urticaria (complete response) compared to 18% of placebo patients.</li>
</ul>
Detailed results from this trial will be provided to the FDA by year-end 2024 in response to the&nbsp;additional data requested&nbsp;for inclusion in the supplemental biologics license application for Dupixent in CSU after <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-20-21-00-00-2764252" rel="noreferrer noopener">rejection</a> in October 2023.
Concurrently, Regeneron Pharmaceuticals and Sanofi announced that a Dupixent&nbsp;(dupilumab) ADEPT Phase 2/3 trial in bullous pemphigoid met the primary and all <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40807652/dupixent-dupilumab-is-the-first-and-only-biologic-to-achieve-significant-improvements-in-disease-r" rel="noreferrer noopener">key secondary endpoints</a>.
Five times more Dupixent patients achieved sustained disease remission in the trial than placebo patients.
For the primary endpoint, 20% of Dupixent patients experienced sustained disease remission at 36 weeks compared to 4% for placebo (p=0.0114).
Sustained disease remission was defined as complete clinical remission with completion of oral corticosteroids (OCS) taper by week 16 without relapse and no rescue therapy use during the 36-week treatment period.
For the components comprising the primary endpoint – with patients having to achieve all components – efficacy among patients receiving Dupixent compared to placebo was as follows:
<ul>
<li>The absence of disease relapse after the patient completed the OCS taper was 59% vs. 16%.</li>
<li>Absence of need for rescue therapy during the treatment period: 42% vs. 12%.</li>
<li>Achievement of complete remission and off OCS by week 16: 38% vs. 27% (not significant).</li>
</ul>
Additionally, a small separate Phase 3 trial (Study A) of Dupixent in adults with uncontrolled and severe chronic pruritus of unknown origin did not achieve statistical significance in its primary itch responder endpoint but showed nominally significant improvements in all other itch endpoints.
The Dupixent Phase 3 program in CPUO consists of Study A and Study B. Study B is planned to initiate as a subsequent pivotal trial.
Price Action: REGN stock closed at $1,136.35, and SNY stock closed at $58.08 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40810215/schlumbergers-breakthrough-in-lithium-production-details" target="_blank" rel="noreferrer noopener">Schlumberger&#8217;s Breakthrough In Lithium Production: Details</a></li>
</ul>

Biotech

Large Cap

Health Care

General

REGN

Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease

Benchmark analyst Fawne Jiang reiterates Grab Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) with a Buy and maintains $6 price target.

GRAB

Benchmark Reiterates Buy on Grab Hldgs, Maintains $6 Price Target

BriaCell Therapeutics Shares Halted On Circuit Breaker To the Downside, Stock Now Up 179.3%

Modine Manufacturing Sets FY27 Target Of 10%-13% Compound Annual Revenue Growth Rate; Sets FY27 Target Of 16%-18% Adjusted EBITDA Margin

Evercore ISI Group analyst Greg Melich maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Outperform and raises the price target from $60 to $65.

Evercore ISI Group Maintains Outperform on Academy Sports, Raises Price Target to $65

Billionaire Elon Musk is the world's richest person and also an influential figure<a href="https://www.benzinga.com/general/education/24/06/39547388/happy-birthday-elon-musk-53-facts-and-figures-about-tesla-spacex-ceo-on-his-53rd-birthday"> across several business segments </a>thanks to his leadership at companies like Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), X, xAI, SpaceX, Neuralink and The Boring Company.
Musk could become a trillionaire in the future, thanks in large part to one of the above companies.
What Happened: Musk&#8217;s wealth is a dream for most and a challenge <a href="https://www.benzinga.com/general/education/24/09/40686893/elon-musk-is-so-rich-that-if-you-printed-1m-a-day-since-the-renaissance-you-still-wouldnt-catch">for others to match.</a>
Currently listed with a wealth of $241 billion, Musk has a near $50-billion lead on second place Jeff Bezos ($198 billion) according to valuation rankings from <a href="https://www.bloomberg.com/billionaires/">Bloomberg</a>.
A new <a href="https://informaconnect.com/academy/companies-entering-trillion-dollar-club-in-2024/">study </a>from Informa Connect Academy found that Musk's wealth grows at an average annual growth rate of 109.9%. While several other billionaires have higher growth rates like Gautam Adani (+122.9%) and Jensen Huang (+111.9%), Musk is predicted to become the world's first trillionaire.
The study projects Musk will reach the wealth milestone by 2027, assuming Tesla maintains its impressive annual growth rate of 173.3%.
Musk's wealth is highly concentrated from stakes of around 13% and 42% in Tesla and SpaceX respectively, with Tesla being the more liquid wealth provider with shares publicly traded, often changing Musk's wealth levels on the daily.
Tesla, which was previously valued at $1 trillion, is expected to return to the limited club of companies worth $1 trillion or more in 2025.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091024">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Informa Connect Academy predicts that Musk will be followed by others in the trillionaire race, with Adani and Huang expected to join in 2028.
Two of the largest gainers in 2024 for wealth have been Huang, gaining $49.6 billion and Meta Platforms CEO Mark Zuckerberg gaining $51.4 billion. Musk, on the other hand, has only gained $11.7 billion in 2024. This ranks sixth among the top 10 richest people.
Musk's wealth has faced wide swings previously. In 2022, Musk saw his wealth fall by more than $180 billion setting a<a href="https://www.benzinga.com/news/23/01/30362822/elon-musk-wins-a-guinness-world-record-but-he-likely-wont-be-celebrating"> new Guinness World Record</a>, with Tesla stock falling over 60% for the year. The high volatility of Musk-linked companies could cause his path to trillionaire status to be faster or slower than the report predicts.
Musk's rival Bezos isn't predicted to become a trillionaire until 2036, with his average annual wealth growing at only 15.3%. While Zuckerberg has the top wealth gain this year, his 35.8% average annual rate is also lower than many top billionaires. Zuckerberg is predicted to become a trillionaire in 2030.
Conglomerate Berkshire Hathaway recently<a href="https://www.benzinga.com/top-stories/24/08/40604676/warren-buffetts-berkshire-hathaway-breaks-1-trillion-poll-points-to-big-pharma-not-tech-as-next-cont"> joined the $1 trillion </a>market capitalization club and the study predicts that Tesla, Taiwan Semiconductor Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) could all join the club in 2025. Eli Lilly came on top in a Benzinga reader poll of which company would top $1 trillion next, after Berkshire Hathaway.
Other future $1 trillion companies are expected to be Novo Nordisk in 2026 and the likes of Exxon Mobil, ASML, and Advance Micro Devices in 2028.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091024">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Topics

Management

AVGO

TSLA

Could Elon Musk Become The World's First Trillionaire? Tesla's Success Could Make It Happen As Early As...

Dividends

Tsakos Energy Navigation Semi-Annual Dividend Of $0.90/Share; Total Dividend For 2024 $1.50

Benchmark analyst John Lawrence reiterates Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Buy and maintains $140 price target.

BOOT

Benchmark Reiterates Buy on Boot Barn Holdings, Maintains $140 Price Target

Affinity has served California&#39;s transportation needs since 1980 and has built longstanding relationships with local businesses and continues to provide California&#39;s Central Valley with superior equipment and services
Affinity Truck Center is a California Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (&quot;HVIP&quot;) certified dealership
&nbsp;
BREA, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- via IBN --&nbsp;<a href="https://www.globenewswire.com/Tracker?data=-jH242Yvb1aVLBHYbYYJQrB4M3ocMnXqR2DkJCkDnrTipk8pImuZxobKi34OKWszGBYqA_12NwaMGPgnyunLlHRWAsgBuzS4zM9HIRh7ZrA=">Mullen Automotive, Inc</a>. (NASDAQ:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=ouVuUHb1CNzJ_NH1WuxQgESaNTKV7B3BfPSTDL6esxMIPSgILd4RmNtp6bhngBxctdQ0Jpwj55tRlPKNYXCtTazGia9ZWTZCX9w_MmbgQhw0I_gj6DF5nf7kCEkMnfAVIDWLT9hwP6XY9kRvn-GXu2U6YlLfxER39jy2klzwBt6P2X4WKWjBzh3HZxqUT7QliG7Fcn-Tp84qFrAKwbNsw9qPKC1m6DZui8Gj6mNWPqnkq9vMpvEEDIreC7TrHl1h">MULN</a>) (&quot;Mullen&quot; or the &quot;Company&quot;), an electric vehicle (&quot;EV&quot;) manufacturer, announces today that its subsidiary, Bollinger Motors (&quot;Bollinger&quot;), has named <a href="https://www.globenewswire.com/Tracker?data=nVCoBjDM7q-2sUx8IotmNsASOceSSLUIWHOVl5BZfQE2FoTsGXKAlSLauDhGT08UAgXFGM7pRtg5--R9hgSMV_L6EwHpO43hZUrEfAXDNOU=">Affinity Truck Center</a> (&quot;Affinity&quot;) as an official Bollinger Motors dealer. Affinity operates sales locations in Bakersfield and Fresno, California, and service locations in Paso Robles and Salinas, California. Affinity Truck Center is a California Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (&quot;<a href="https://www.globenewswire.com/Tracker?data=GetzZw9PbuLAxlHwvOZZzgRDxT04tPxW0F-VuD6Nt1TcxyeuKq6CplD8CIVByGSVFLp57jpyu9Uz8H4VMsrsLQ==">HVIP</a>&quot;) certified dealership.

MULN

Mullen's Bollinger Motors Adds Affinity Truck Center To Its Retail Network

Mira Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NYSE">MIRA</a>) short percent of float has risen 2572.22% since its last report. The company recently reported that it has 447 thousand shares sold short, which is 4.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Mira Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726061422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mira Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Mira Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Mira Pharmaceuticals's peer group average for short interest as a percentage of float is 2.53%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

ADS-TEC Energy

ADS-TEC Energy (ADSEW) Forecast

ADS-TEC Energy (NASDAQ:ADSEW) Stock, Quote.Headers.trade-ideas